Blog
Indivior Receives FDA Approval for OPVEE (nalmefene)
Indivior’s OPVEEĀ® (nalmefene) nasal spray has received FDA approval for the emergency treatment of opioid overdose in adults and pediatric ...
Epkinly: FDA-Approved Bispecific Antibody for DLBCL
On May 19, 2023, AbbVie announced that the U.S. Food and Drug Administration (FDA) granted approval to EPKINLYTM (epcoritamab-bysp) as ...
LEXICON ANNOUNCES FDA APPROVAL OF INPEFA (SOTAGLIFLOZIN) FOR TREATMENT OF HEART FAILURE
Lexicon Pharmaceuticals on May 26, 2023 announced that the US Food and Drug Administration (FDA) has approved INPEFAā¢ (sotagliflozin), a once-daily ...
ALLERGANāS LATEST SKIN-SMOOTHING PRODUCT HAS RECEIVED FDA APPROVAL, FEATURING A UNIQUE DELIVERY MECHANISM
Allergan has recently obtained FDA approval for its groundbreaking skincare product, Skinvive, which is part of the Juvederm dermal filler ...
EPCORITAMAB RECEIVES FDA APPROVAL FOR RELAPSED/REFRACTORY DLBCL
The FDA has granted approval to epcoritamab-bysp (Epkinly), the first T-cellāengaging bispecific antibody, for the treatment of relapsed/refractory diffuse large ...
![THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ISSUED A COMPLETE RESPONSE LETTER CONCERNING [VIC-]TRASTUZUMAB DUOCARMAZINE, A PRODUCT DEVELOPED BY BYONDIS.](https://pharmtales.com/wp-content/uploads/2023/06/FDA-Issues-Response-Letter-on-Byondis-Trastuzumab-Duocarmazine.jpg)
FDA Issues Response Letter on Byondis’ Trastuzumab Duocarmazine
Byondis B.V., a Dutch clinical-stage biopharmaceutical company specializing in precision medicines, has announced today that the U.S. Food and Drug ...
